-
One-step TUNEL Cy3 Kit for Apoptosis Research
2026-09-03
The One-step TUNEL Cy3 Apoptosis Detection Kit connects terminal deoxynucleotidyl transferase (TdT) labeling with spatial and quantitative analysis of apoptotic DNA fragmentation. This article explains how to use the assay to interpret hepatocyte injury, pathway modulation, and translational apoptosis data without overstating what TUNEL can prove.
-
Live-Dead Cell Staining Kit: Workflow Guide
2026-09-02
Build a practical cell viability assay around Calcein-AM and Propidium Iodide dual staining for microscopy, flow cytometry, cytotoxicity studies, and biomaterial screening. This guide combines executable starting conditions with controls, interpretation rules, and troubleshooting for more reproducible live/dead measurements.
-
Demethyleneberberine Blocks IL-1β Maturation
2026-09-02
The reference study identifies a mitochondrial mechanism by which Demethyleneberberine suppresses inflammatory IL-1β maturation in ulcerative colitis models. Its combination of DSS-induced colitis, macrophage systems, genetic controls, and mitochondrial perturbation provides a useful framework for evaluating DMB as a mechanism-oriented anti-inflammatory compound.
-
Firefly Luciferase mRNA Workflow Guide
2026-09-01
Firefly Luciferase mRNA (ARCA, 5-moUTP) provides a sensitive, non-DNA readout for delivery efficiency, transient gene expression, cell viability assay development, and in vivo imaging mRNA workflows. This guide translates its cap, nucleotide, and poly(A)-tail design into practical assay setup, nanoparticle screening, and troubleshooting decisions.
-
ETS1–SENP2 Signaling in Bronchopulmonary Dysplasia
2026-09-01
The reference study identifies ETS1 as a transcriptional regulator of mitochondrial quality control in hyperoxia-induced bronchopulmonary dysplasia. Its central mechanism links ETS1-driven SENP2 expression to FUNDC1 deSUMOylation, HSPA8-dependent FUNDC1 degradation, and suppression of excessive mitophagy, although the reported abstract contains one structural-outcome phrase that requires verification against the full article.
-
Protein A/G Magnetic Co-IP/IP Kit Workflow
2026-08-31
Build faster, more reproducible immunoprecipitation workflows for protein-complex isolation, western blotting, mass spectrometry, and antibody purification. Magnetic separation and broad Fc-region binding make this format especially useful when sample quantity, complex stability, or processing time is limiting.
-
Tariquidar: A Mechanobiology Probe for P-gp
2026-08-31
Tariquidar (XR9576) helps distinguish acute P-glycoprotein inhibition from viscosity-driven transporter upregulation. This article translates new tumor-mechanobiology findings into assay design, controls, and interpretation for drug resistance research.
-
Blebbistatin: Mechanism, Uses, and Assay Limits
2026-08-30
(±)-Blebbistatin is a cell-permeable non-muscle myosin II inhibitor that targets the myosin-ADP-Pi intermediate and suppresses actin-activated ATPase activity. Its reversible control of contractility makes Blebbistatin useful for cell migration, adhesion, morphology, and cytoskeletal dynamics assays, but isoform selectivity, solvent handling, and assay-specific potency must be controlled.
-
Olaparib: DNA Repair Meets Immune Reprogramming
2026-08-29
Olaparib and AZD2281 are moving beyond a narrow DNA repair narrative. This thought-leadership guide connects PARP-1/2 inhibition with BRCA-context biology, tumor radiosensitization studies, and emerging combination strategies that address T cell exhaustion in BRCA1-deficient ovarian cancer.
-
Berberine Targets RAGE/POMC in Metabolic Disease
2026-08-28
A 2026 pre-proof study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and connects RAGE/POMC signaling with hypothalamic neuronal apoptosis, autophagy, and glucolipid regulation. Its integrated computational, cellular, and mouse-model design provides a useful framework for studying neuronal mechanisms of metabolic disease while leaving translation to neurodegenerative disorders unresolved.
-
SAN-Plexus Assembloids and Pacemaker Maturation
2026-08-28
This Cell Stem Cell study develops human pluripotent stem cell-derived sinoatrial node–cardiac plexus assembloids that reproduce key structural, molecular, and electrophysiological features of neuro-modulated pacemaker systems. By combining assembloid function with spatial transcriptomics of human sinoatrial node tissue, the authors identify a prosaposin–GPR37 signaling axis associated with pacemaker maturation and establish a platform for studying conduction dysfunction.
-
Tetrazolium (chloride) Workflows for Viability
2026-08-27
Tetrazolium (chloride), also called Tetrazolium Red, converts mitochondrial dehydrogenase activity into a visible red formazan signal for cell and tissue analysis. This guide connects plate-based viability assays with ischemic brain staining, emphasizing controls, quantification, and troubleshooting rather than treating color intensity as a standalone mechanistic answer.
-
RBMS1 Loss Rewires PD-L1 Immunity in TNBC
2026-08-27
The reference study identifies RBMS1 as an RNA-binding protein that sustains PD-L1 stability in immune-cold triple-negative breast cancer through B4GALT1-dependent glycosylation. Its depletion increased tumor-cell susceptibility to T-cell attack and improved responses to immune-based treatments, providing a mechanistic framework for combination strategies.
-
Carboplatin Workflows for Cancer Research
2026-08-26
Carboplatin is a platinum-based DNA synthesis inhibitor that supports reproducible cytotoxicity, DNA-damage, and resistance studies across ovarian and lung cancer models. This workflow emphasizes stock preparation, matched 2D–3D testing, proteomics-informed interpretation, and troubleshooting for variable drug response.
-
Serine/Glycine-Free Diet in CRC Immunity
2026-08-26
Tong et al. show that a serine/glycine-free diet can restrict colorectal cancer growth while increasing cytotoxic T-cell activity, yet simultaneously promote immune escape through PD-L1 lactylation. The study links dietary metabolism to checkpoint regulation and provides early clinical evidence that this intervention is feasible and safe, supporting combination strategies rather than diet-only treatment.